# Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals

> **NCT02980016** · PHASE3 · COMPLETED · sponsor: **The Aurum Institute NPC** · enrollment: 4027 (actual)

## Conditions studied

- Tuberculosis
- HIV

## Interventions

- **DRUG:** rifapentine + isoniazid
- **DRUG:** Isoniazid

## Key facts

- **NCT ID:** NCT02980016
- **Lead sponsor:** The Aurum Institute NPC
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2019-10-18
- **Final completion:** 2019-10-18
- **Target enrollment:** 4027 (ACTUAL)
- **Last updated:** 2019-10-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02980016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02980016, "Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02980016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*